<DOC>
	<DOCNO>NCT00111696</DOCNO>
	<brief_summary>To describe tumor tissue saturation MEDI-522 patient advance malignant melanoma .</brief_summary>
	<brief_title>Study Tumor Saturation Biological Activity MEDI-522 ( Abergrin ) Patients With Advanced Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm , unresectable , Stage IV recurrent malignant melanoma ( base American Joint Committee Cancer [ AJCC ] stag ) Prior therapy chemotherapy and/or immunotherapy malignant melanoma allow , provide therapy end prior study entry treatment related toxicity resolve Measurable disease ( base Response Evaluation Criteria Solid Tumors [ RECIST ] criterion ) define least one lesion accurately measure least one dimension ( long diameter record ) great equal 20 mm conventional technique , great equal 10 mm spiral compute tomography ( CT ) scan Have melanoma biopsied , least twice , MEDI522 treatment Males females least 18 year age time study entry Women reproductive potential ( define &lt; 1 year postmenopausal ) must negative serum B human chorionic gonadotropin ( bHCG ) pregnancy test within 3 day prior study entry ; men woman reproductive potential must agree practice effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device [ IUD ] , condom , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) time inform consent sign ( woman ) time initiation MEDI522 ( men ) , must agree continue use precaution receive MEDI522 30 day final dose MEDI522 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 16 week WBC great equal 3000/mm ( 3 ) , absolute neutrophil count ( ANC ) great equal 1,500/mm ( 3 ) , platelet count great equal 100,000/mm ( 3 ) Bilirubin great equal 1.5 mg/dL [ unless due Gilbert 's syndrome ( unconjugated hyperbilirubinemia ) case bilirubin &lt; = 3.5 mg/dL ] ; aspartate transaminase ( AST ) /alanine transaminase ( ALT ) great equal 3 x upper limit normal ( ULN ) ; serum creatinine great equal 1.5 mg/dL ; hepatic alkaline phosphatase great equal 3.0 x ULN ; prothrombin time ( PT ) international normalize ratio ( INR ) within normal range ( unless patient receive anticoagulation therapy ) ; partial thromboplastin time ( PTT ) within normal range Patients prior radiation therapy eligible , provided therapy palliative nature , area tumor biopsied , radiationrelated toxicity resolve Patients prior major surgery eligible least 4 week pass since surgery . All surgical wound must heal . All toxicity relate prior adjuvant therapy must resolve . Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization obtain patient prior receipt study medication begin study procedure Pregnancy nurse Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy treatment cancer Current plan participation ( day study entry 30 day last dose MEDI522 ) research protocol investigational agent may administer Received investigational agent within 4 week prior study entry Known brain metastasis primary brain tumor History prior malignancy within past 5 year nonmelanomatous skin cancer control , carcinoma situ cervix , T1a T1b prostate cancer note incidentally transurethral resection prostate ( TURP ) prostatespecific antigen ( PSA ) value within normal limit since TURP , superficial bladder cancer Any evidence history , elicit investigator , symptomatic cerebrovascular event ( i.e. , stroke transient ischemic attack ) within 6 month prior study entry ; history evidence pulmonary embolism thrombophlebitis ( include deep vein thrombosis ) require anticoagulant therapy ( e.g. , warfarin heparin ) . Currently require anticoagulation ( exclude use heparin flush solution maintenance catheter line ) thromboembolic disease base medical history physical examination Any current evidence hematemesis , melena , hematochezia , gross hematuria History presence bleeding diatheses Elective surgery plan study period 30 day last dose MEDI522 History hypersensitivity previously administer monoclonal antibody History immunodeficiency Patients clinical diagnosis Acquired Immune Deficiency Syndrome ( AIDS ) know active viral hepatic infection A prior myocardial infarction angina , uncontrolled/refractory hypertension within 6 month prior study entry Any evidence active infection require parenteral antiinfective therapy Prior treatment MEDI522 MEDI523 A general medical psychological condition behavior , include substance dependence abuse , opinion investigator , might permit patient complete study sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>